Resetting Priorities
The already challenging path to an HIV vaccine takes a hard turn after recent clinical trials
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
September 22, 2008 Cover
Volume 86, Issue 38
The already challenging path to an HIV vaccine takes a hard turn after recent clinical trials
The already challenging path to an HIV vaccine takes a hard turn after recent clinical trials
Alterations in volatile chemicals emitted by humans could be used as biomarkers to diagnose the disease
Drug companies reverse course and boost donations to Democrats
New dyes open door to biomedical applications of near-IR imaging
Custom manufacturers of pharmaceutical actives and intermediates vie for a position in new big pharma supply chains
After more than a decade, EPA's program has not begun screening a single chemical
Rational design leads to novel drug candidate, now in clinical trials